Modulators of hedgehog signaling pathway

A method for modulating differentiated state, survival, and/or proliferation of a cell, the method comprising contacting the cell with a glucocorticoid, or a compound of formula (I):

• wherein:
• R11 is independently for each occurrence optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, OR14, NO2, CN, CF3, halo, C(O)R14, CO2R14, SOR14, SO2R14, or N(R15);
• R12 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, OR14, C(O)R14, or CO2R14;
• R13 is independently for each occurrence optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, OR14, NO2, CN, CF3, halo, C(O)R14, CO2R14, SOR14, SO2R14, or N(R15);
• R14 is independently for each occurrence optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• R15 is independently for each occurrence H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, C(O)R14, or CO2R14;
• m is 0, 1, 2, 3, 4, or 5;
• n is 0, 1, 2, 3, 4, or 5;
• and
• isomers and pharmaceutically acceptable salts thereof,
• or a compound of formula (II):
• wherein:
• R21 is independently for each occurrence optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, OR24, NO2, CN, CF3, halo, OC(O)R24, C(O)R24, CO2R24, C(O)N(R24)2, SOR24, SO2R24, N(R24)2, NHC(O)R24, NHCO2R24, or two R21s together with the carbons they are attached to form an optionally substituted 5-8 member cyclyl or an optionally substituted 5-8 member heterocyclyl;
• R22 and R23 are independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted —(CH2)t—R24, or R22 and R23 together with the nitrogen they are attached to form an optionally substituted 5-8 membered ring;
• R24 is independently for each occurrence optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• p is 0, 1, 2, 3, 4, or 5;
• q is 1, 2, 3, 4, 5, or 6;
• t is 1, 2, 3, 4, 5, or 6;
• and
• isomers and pharmaceutically acceptable salts thereof,
• and any combinations thereof.

A method for treating or preventing cancer, a precancerous condition and/or metastasis, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I):

• wherein:
• R11 is independently for each occurrence optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, OR14, NO2, CN, CF3, halo, C(O)R14, CO2R14, SOR14, SO2R14, or N(R15);
• R12 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, OR14, C(O)R14, or CO2R14;
• R13 is independently for each occurrence optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, OR14, NO2, CN, CF3, halo, C(O)R14, CO2R14, SOR14, SO2R14, or N(R15);
• R14 is independently for each occurrence optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• R15 is independently for each occurrence H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, C(O)R14, or CO2R14;
• m is 0, 1, 2, 3, 4, or 5;
• n is 0, 1, 2, 3, 4, or 5;
• and
• isomers and pharmaceutically acceptable salts thereof,
• or a compound of formula (II):
• wherein:
• R21 is independently for each occurrence optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, OR24, NO2, CN, CF3, halo, OC(O)R24, C(O)R24, CO2R24, C(O)N(R24)2, SOR24, SO2R24, N(R24)2, NHC(O)R24, NHCO2R24, or two R21s together with the carbons they are attached to form an optionally substituted 5-8 member cyclyl or an optionally substituted 5-8 member heterocyclyl;
• R22 and R23 are independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted —(CH2)rR24, or R22 and R23 together with the nitrogen they are attached to form an optionally substituted 5-8 membered ring;
• R24 is independently for each occurrence optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• p is 0, 1, 2, 3, 4, or 5;
• q is 1, 2, 3, 4, 5, or 6;
• t is 1, 2, 3, 4, 5, or 6;
• and
• isomers and pharmaceutically acceptable salts thereof,
• and any combinations thereof.